medigraphic.com
SPANISH

Acta Médica del Centro

ISSN 1995-9494 (Electronic)
Revista del Hospital Clínico Quirúrgico "Arnaldo Milián Castro"
  • Contents
  • View Archive
  • Information
    • General Information        
    • Directory
  • Publish
    • Instructions for authors        
  • medigraphic.com
    • Home
    • Journals index            
    • Register / Login
  • Mi perfil

2021, Number 4

<< Back Next >>

Acta Med Cent 2021; 15 (4)

Terapia con biomodulina T en pacientes vulnerables a COVID-19

Madrigal ML, Yanes MB, Hernández FME
Full text How to cite this article

Language: Spanish
References: 12
Page: 488-496
PDF size: 470.25 Kb.


Key words:

biomodulin T, COVID-19, personal pathological history.

ABSTRACT

Introduction: the biomodulin T has cyto-restorative and immunomodulatory action by stimulating lymphoblastoid mitosis, in that way the differentiation of T-lymphocytes is normalized; in models of acute inflammation, edema and chronic inflammation showed an anti-inflammatory effect by modulating the induced inflammatory response.
Objective: to evaluate the therapeutic response of biomodulin T in susceptible patients to SARS-CoV-2.
Methods: a descriptive, prospective longitudinal study was carried out at the Immunology Clinic from “Arnaldo Milián Castro” Hospital, in Villa Clara Province, from March 2020 to September 2020. A total of 52 patients who presented personal pathological antecedents that made them susceptible to suffer from SARS CoV-2 virus infection were studied.
Results: descriptive statistical methods such as frequency tables for the variables age, sex, personal pathological history and response to treatment with biomodulin T were applied. The age group with the most comorbidities was 40 to 59 years, male sex predominated and most patients had a history of chronic obstructive pulmonary disease, diabetes mellitus and arterial hypertension. The largest number of patients had a diagnosis of autoimmune diseases.
Conclusions: the therapeutic response was satisfactory for all age groups.


REFERENCES

  1. Madrigal Mora L, Ferriol González MR, Meneses Foyo A. Rendimiento académico y factores estresantes en residentes de especialidades quirúrgicas en su examen estatal con enfrentamiento a la COVID-19. I Jornada Científica de Farmacología y Salud. Fármaco Salud Artemisa 2021 [Internet]. Artemisa: Universidad de Ciencias Médicas de Artemisa; 2021 [citado 03/03/2020]. Disponible en: https://farmasalud2021.sld.cu/index.php/farmasalud/2021/paper/viewFile/108/48

  2. Yang J, Zheng Y, Gou X, Pu K, Chen Z, Guo Q, et al. Prevalence of comorbidities in the Novel Wuhan Coronavirus (COVID-19) infection: a systematic review and meta-analysis. J Inter Infect Dis [Internet]. 2020 [citado 03/03/2020];94(10):91-5. Disponible en: https://pubmed.ncbi.nlm.nih.gov/32173574/. https://doi.org/10.1016/j.ijid.2020.03.017

  3. Centro para el Control Estatal de Medicamentos, Equipos y Dispositivos Médicos. Biomodulina T [Internet]. La Habana: Cecmed; 2015 [citado 03/03/2020]. Disponible en: https://www.cecmed.cu/sites/default/files/adjuntos/rcp/biologicos/rcp_biomodulina.pdf

  4. Samada Suárez M, Hernández Perera JC. ¿Predomina la mortalidad por la COVID-19 en el sexo masculino? Boletín científico del CIMEQ [Internet]. 2020 [citado 03/03/2020];1(15):6-7. Disponible en: https://instituciones.sld.cu/bolcimeq/2020/06/29/predomina-la-mortalidad-por-la-covid-19-en-el-sexo-masculino/

  5. Centro de Estudios Demográficos. Edición Especial COVID-19. Boletín INFOPOB [Internet]. 2020 [citado10/09/2020];(10):[aprox. 19 p.]. Disponible en: https://covid19cubadata.github.io/boletines/infopob-10-20200910.pdf

  6. Agencia Cubana de Noticias. COVID-19: En Cuba, como en el mundo, la edad de contagio se ha “corrido” [Internet]. La Habana: ACN; 2020. [citado 12/12/2020]. Disponible en: http://www.acn.cu/cuba/70293-covid-19-en-cuba-como-en-el-mundo-la-edad-de-contagio-se-ha-corrido

  7. Mizumoto K, Kagaya K, Zarebski A, Chowell G. Estimating the asymptomatic proportion of coronavirus disease 2019 (COVID-19) cases on board the Diamond Princess cruise ship, Yokohama, Japan, 2020. Euro Surveill [Internet]. 2020 [citado 05/05/2020];25(10):2000180. Disponible en: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7078829/. https://dx.doi.org/10.2807/1560-7917.ES.2020.25.10.2000180

  8. Almaguer Mederos LE, Cuello Almarales D, Almaguer Gotay D. Rol de los genes ACE2 y TMPRSS2 en la susceptibilidad o gravedad de la COVID-19. AACC [Internet]. 2020 [citado 25/05/2020];10(2):e799. Disponible en: http://www.revistaccuba.sld.cu/index.php/revacc/article/view/799/860

  9. Chen N, Zhou M, Dong X, Qu J, Gong F, Han Y. Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study. Lancet [Internet]. 2020 [citado 25/05/2020];395(10223):507-513. Disponible en: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7135076/. https://dx.doi.org/10.1016/S0140-6736(20)30211-7

  10. Paules CI, Marston HD, Fauci AS. Coronavirus Infections-More Than Just the Common Cold. JAMA [Internet]. 2020 [citado 25/05/2020];323(8):707-708. Disponible en: https://jamanetwork.com/journals/jama/fullarticle/2759815. https://doi.org/10.1001/jama.2020.0757

  11. Peláez O. Biomodulina T, otro eficaz fármaco cubano contra la COVID-19. Granma [Internet]. 11/05/2020 [citado 17/12/2020]. Disponible en: https://www.granma.cu/cuba-covid-19/2020-05-11/biomodulina-t-otro-eficaz-farmaco-cubano-contra-la-covid-19-11-05-2020-00-05-53

  12. Ministerio de Salud Pública. Protocolo de Actuación Nacional para la COVID-19 (Versión 1.3 Abril) [Internet]. La Habana: MINSAP; 2020 [citado 04/05/2020]. Disponible en: https://covid19cubadata.github.io/protocolos/protocolo-version-3.pdf




2020     |     www.medigraphic.com

Mi perfil

C?MO CITAR (Vancouver)

Acta Med Cent. 2021;15